Cancer Progress 2014 Presentations

Cancer Progress 2014 Presentations

Tuesday, March 4, 2014
8:00 – 8:15am Opening Address: A Quick Survey – Thinking 25 Years Backwards & Forwards
  • Jeff Bockman, PhD, VP, Defined Health
8:15 – 8:45am The State of Play in Immuno-Oncology
  • Axel Hoos, MD, PhD, VP, Oncology Research and Development, GlaxoSmithKline
8:45 – 10:00am Taking Immunotherapy Seriously: New Targets and Combinations
Moderator:

  • Axel Hoos, MD, PhD, VP, Oncology Research and Development, GlaxoSmithKline

Panelists:

  • Jeff Bockman, PhD, VP, Defined Health
  • Ira Mellman, PhD, VP, Research Oncology, Genentech
  • Galit Rotman, PhD, Chief Scientist of Therapeutics, Compugen
  • Michel Sadelain, MD, PhD, Director, Center for Cell Engineering, Memorial Sloan Kettering Cancer Center
  • Lauren V. Wood, MD, Senior Clinical Investigator, Vaccine Branch, National Cancer Institute
10:30 – 11:45am Brain Cancer – Tackling the Intractable: Novel Targets and Approaches
Moderator:

  • Minesh P. Mehta, MD, Medical Director, Maryland Proton Treatment Center, University of Maryland

Panelists:

  • Lauren Abrey, MD, Oncology Development Site Head, F. Hoffmann-La Roche Inc.
  • Thomas Davis, MD, CMO and SVP Clinical Development, Celldex Therapeutics
  • H. Ian Robins, MD, PhD, Faculty, University of Wisconsin School of Medicine and Public Health
  • Eric Rowinsky, MD, Chief Medical Officer, Head of Research & Development, Stemline Therapeutics
11:45 – 1:00pm Big Data and Cancer: Transforming Patient Care by Turning Data into Decisions
Moderator:

  • Colin Hill, Chief Executive Officer, President & Chairman, GNS Healthcare

Panelists:

  • Alexis Borisy, Entrepreneur in Residence, Third Rock Ventures
  • Joel Dudley, PhD, Director of Biomedical Informatics and Assistant Professor of Genetics and Genomics Sciences, Icahn School of Medicine at Mount Sinai
  • Brian Leyland-Jones, MD, VP, Molecular and Experimental Medicine, Avera Health
  • Michael Kolodziej, MD, National Medical Director, Oncology Solutions, Aetna
  • Timothy J. Thompson, CEO, Intervention Insights
2:15 – 3:30pm Evidentiary Standards for Diagnostics: When does a Biomarker Become a Diagnostic for Cancer Treatment?
Moderator:

  • Steven Averbuch, MD, VP, Translational Clinical Development & Pharmacodiagnostics, Bristol-Myers Squibb Company

Panelists:

  • Anna Barker, PhD, Director, Transformative Healthcare Networks, Arizona State University
  • Richard Brian Gaynor, MD, VP, Product Development/Medical Affairs, Eli Lilly and Company
  • Steven Gutman, MD, Strategic Advisor, Myraqa
  • Michael Kolodziej, MD, National Medical Director, Oncology Solutions, Aetna
  • Howard I. Scher, MD, Chief, Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center
  • Kim Zerba, PhD, Group Director, Global Biometric Sciences, Bristol-Myers Squibb
4:00 – 5:15pm Oncology R&D: ROI and the New Expectations
Moderator:

  • Steve Heller, Principal, OncStrat LLC

Panelists:

  • Walter Capone, President, The Multiple Myeloma Research Foundation
  • Jeanne Farrell, PhD, Business Development Director, Icahn School of Medicine at Mount Sinai • Debasish Roychowdhury, MD, President, Nirvan Consultants, LLC
  • Mark J. Simon, Advisor, Torreya Partners LLC
5:15 – 6:30pm New Treatment Options for Prostate Cancer
Moderator:

  • Jeremy P. Goldberg, President, JPG Healthcare LLC

Panelists:

  • Richard Brian Gaynor, MD, VP, Product Development/Medical Affairs, Eli Lilly and Company
  • Marco Gottardis, Ph D, VP and Prostate Cancer Disease Area Stronghold Leader, Oncology Therapeutic Area, Janssen Research & Development, LLC
  • Richard Heyman, CEO, Seragon (ex-CEO Aragon)
  • Philip Kantoff, MD, Director, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute
  • Marianne Sadar, PhD, Distinguished Scientist, BC Cancer Agency. Professor of Pathology and Laboratory Medicine, University of British Columbia
Tuesday, March 5, 2014
8:00 – 8:15am Opening Remarks
  • Mike Rice, MS, MBA, Senior Consultant, Defined Health
8:15 – 9:15am Keynote Address – A Trialogue: Valuing Value in Oncology
Moderator:

  • Ed Saltzman, President, Defined Health

Panelists:

  • Peter Bach, MD, Attending Physician, Memorial Sloan-Kettering Cancer Center
  • Professor David Haslam, CBE, FRCGP, FRCP, FFPH Chairman, NICE
  • Clifford A. Hudis, MD, Chief, Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, 2013-2014 President, ASCO
9:15 – 10:30am Antibody-Drug Conjugates: Supercharging the Blockbuster Antibody Class
Moderator:

  • Jeff Bockman, PhD, VP, Defined Health

Panelists:

  • Robert Cohen, MD, Calico Life Sciences
  • Jonathan Drachman, MD, SVP, Research and Translational Medicine, Seattle Genetics
  • Hans-Peter Gerber, PhD, VP, BioConjugate Discovery & Development, Oncology Research, Pfizer
  • John Lambert, PhD, EVP, Research & Development & Chief Scientific Officer, ImmunoGen, Inc.
  • Peter Kiener, Ph D, Chief Scientific Officer, Ambrx, Inc.
10:45 – 12:00pm Cancer Gene & Cell Therapy: Expanding Therapeutic Options with Living Drugs
Moderator:

  • Mike Rice, MS, MBA, Senior Consultant, Defined Health

Panelists:

  • Estuardo Aguilar-Cordova, PhD, Chief Executive Officer Advantagene, Inc.
  • Renier J. Brentjens, MD, PhD, Director, Cellular Therapeutics, Memorial Sloan Kettering Cancer Center
  • Nori Kasahara, M.D., Ph.D., Director, CURE Vector Core Facility JCCC Vector Shared Resources, Professor, Department of Medicine, Molecular & Medical Pharmacology, UCLA
  • Angela Shen, MD, MBA, Global Clinical Program Head, CTL019, Oncology Clinical Development, Novartis Pharmaceuticals Corp
12:00 – 1:15pm Intrinsic and Acquired Resistance in Cancer: Getting Smarter About Combinations and Sequencing
Moderator:

  • Neal Rosen, MD, PhD, Director, Center for Mechanism-Based Therapeutics, Memorial Sloan Kettering Cancer Center

Panelists:

  • Jeffrey A. Engelman, MD, PhD, Director of Thoracic Oncology and Director of Molecular Therapeutics, Massachusetts General Hospital Cancer Center
  • Greg Plowman, MD, PhD, VP, Oncology Research Eli Lilly and Company
  • David Solit, MD, Director, Developmental Therapeutics, Memorial Sloan Kettering Cancer Center
2:30 – 3:45pm Challenging Established Paradigms in Cancer
Moderator:

  • Sol J. Barer, PhD, SJBarer Consulting LLC

Panelists:

  • Rajesh Chopra, MD, PhD, Corporate VP, Translational and Early Drug Development, Celgene Corporation
  • Giulio Draetta, MD, PhD, Director, Institute for Applied Cancer Science, Professor, Genomic Medicine, MD Anderson Cancer Center
  • Tak Mak, PhD, University Professor, Ontario Cancer Institute, University of Toronto
  • Neal Rosen, MD, PhD, Director, Center for Mechanism-Based Therapeutics, Memorial Sloan Kettering Cancer Center
4:00 – 5:15pm Translational Oncology: How to Better Transform Targets into Relevant Drugs for Patients
Moderators:

  • Jeffrey M. Bockman, PhD, VP, Defined Health
  • Mike Rice, MS, MBA, Senior Consultant, Defined Health

Panelists:

  • Joseph Beechem, PhD, SVP, Research and Development, NanoString Technologies
  • Pamela Carroll, PhD, VP, Oncology, Innovation Center in Boston, Janssen Research & Development
  • Rajesh Chopra, MD, PhD, Corporate VP, Translational and Early Drug Development, Celgene Corporation
  • Victoria Richon, PhD, VP and Head of Cancer Research, Discovery and Early Development, Sanofi
  • Spiro G. Rombotis, President & CEO, Cyclacel Pharmaceuticals, Inc.